Radiomics Analysis of Focal Liver Lesions Based on Contrast-Enhanced Ultrasound Imaging

Research on Key Techniques for Intelligent Diagnosis and Ablation Decision-making of Liver Cancer and Evolution by Contrast-enhanced Ultrasound

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04682886

Enrollment

5000

Registered

2020-12-24

Start date

2017-01-01

Completion date

2025-12-31

Last updated

2020-12-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Contrast-enhanced Ultrasound, Focal Liver Lesions

Brief summary

Contrast-enhanced ultrasound (CEUS) substantially improves the potential of ultrasound (US) for the identification and characterization of focal liver lesions (FLLs). Compared to contrasted-enhanced MRI and CT, it has some unique advantages, such as the absence of ionizing radiation, and easy operability and repeatability. However, the efficacy of CEUS in diagnosing liver lesions is challenged by several factors including being highly dependent on doctor's experience, low signal-to-noise ratio, and low interobserver agreement. Therefore, it is a beneficial attempt to construct an intelligent CEUS diagnosis system using digital information technology. This study aims to collect standard data of CEUS cines recordings and develop deep learning model for accurate segmentation, detection and classification of liver lesions.

Interventions

DIAGNOSTIC_TESTdiagnosis

there is no intervention diagnosis or treatment for patients

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

1. patients with a solid liver tumor visible during routine ultrasound and received CEUS. 2. disease history and standard of reference of the lesions can be acquired

Exclusion criteria

1. hypersensitivity for ultrasound contrast media 2. pregnant or lactating patients 3. previously treated lesions or local relapse from previously treated lesions 4. diffuse tumors

Design outcomes

Primary

Measure	Time frame	Description
AUC value	through study completion, an average of 7 year	Area under the receiver operating characteristic (ROC) curve (AUC）
specificity	through study completion, an average of 7 year	diagnosis specificity of intelligent CEUS analysis
sensitivity	through study completion, an average of 3 year	diagnosis sensitivity of intelligent ultrasound analysis

Countries

China

Contacts

Primary ContactJie Yu, Dr

jiemi301@163.com15901417963

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 6, 2026